A studio service
Swiss biotech pitch deck design translating science into Swiss institutional capital.
Switzerland is the world's most concentrated life sciences cluster, home to Roche, Novartis, and premier research hubs like ETH Zurich and the Biozentrum Basel. Raising biotech capital here requires an uncommon balance: uncompromising molecular scientific precision paired with clear commercial asset valuation.
Investment
Three ways to raise.
Fixed price, fixed scope. Pick the tier that matches your raise — from a single deal deck to a full capital-raise kit.
Essential
A focused deck for a single asset or a partnering round - you bring the data, we design it.
5-7 business days
- 12-15 designed slides
- Pipeline table and mechanism diagram
- Data figures redrawn to publication standard
- Every claim footnoted to your source
- 1 revision round
- Editable PowerPoint source files
Standard
The full raise or partnering push: we shape the narrative, build the figures and cut the short version.
Priority - 4-5 business days
- 18-25 designed slides
- We build the narrative from your inputs
- Full figure set - efficacy, safety, IP timeline
- Non-confidential partnering version
- 2 revision rounds
- Editable PowerPoint + source files
Complete
Everything a conference season needs - deck, appendix, one-pager and the data-room set.
Rush available
- 30-50 slides - deck plus appendix
- Company presentation and partnering versions
- Non-confidential one-pager for the leave-behind
- Data-room slide set
- 3 revision rounds, white-glove
- 60-minute strategy call + all source files
N° 01The Swiss biotech barrier
Four pitfalls in life science capital raises.
01
Academic overload vs commercial narrative
Founders from academic spinouts often present 40 slides of gel electrophoresis and raw microscopy without answering the drug's target product profile (TPP) or pricing.
02
Illegible Mechanism of Action (MoA)
Copy-pasted journal figures with low DPI graphics undermine trust. Specialized biotech investors need clean, professional vector MoA illustrations.
03
Vague regulatory and clinical roadmap
Swiss and European life sciences funds demand clear milestone gates: IND enablement, Phase Ia/Ib cohorts, Swissmedic/EMA/FDA scientific advice, and readout timelines.
04
Lack of commercial partnering strategy
Are you developing through Phase II for Big Pharma out-licensing or taking the asset to commercialization? Ambiguity on partnering deal value weakens your valuation.
N° 02What we design
The slides that unlock European & global capital.
01
Mechanism of Action (MoA) architecture
Custom-illustrated vector biological cascades: receptor binding, enzymatic pathways, cell therapies, or small-molecule targets rendered with peer-reviewed clarity.
02
Clinical pipeline & milestone Gantt
Preclinical, Phase 1, Phase 2, and regulatory readout timelines explicitly mapped against capital tranches and inflection valuations.
03
Target Product Profile (TPP) comparison
Side-by-side differentiation against existing standard of care (SoC) and emerging pipeline competitors on efficacy, safety, and dosing route.
04
IP & patent exclusivity landscape
Composition of matter, method of use, and formulation patent expiration timelines across Switzerland, the EU, US, and Asia.
Sample slides
Sample slides, in house style.
Generated in our editorial discipline — framed to your vertical. Every deck we ship is original and bespoke.
Questions
The answers we give most often.
- Do you understand European and Swiss regulatory frameworks?
- Yes. We design clinical pipeline roadmaps specifically around EMA, Swissmedic, and FDA clinical phase gates, orphan drug designations, and prime pathways.
- Can you redraw our scientific figures and Mechanism of Action diagrams?
- Yes. We transform rough PowerPoint sketches or low-res paper figures into publication-grade vector illustrations that make complex biology immediately digestible.
- Which Swiss life science conferences do you design for?
- We design decks for BIO-Europe, Swiss Biotech Day in Basel, J.P. Morgan Healthcare Conference, Biotech Showcase, and private Swiss angel/family office partnering syndicates.
- How much does a biotech deck cost?
- Biotech pitch decks start at $4,000 for standard investor presentations. Our Complete package ($7,500) includes custom scientific Mechanism of Action vector diagrams, comprehensive clinical Gantt charts, and non-confidential partnering teasers.
Next step
Raising for your Swiss life sciences company?
Send us your clinical data and pipeline milestones. We'll design a presentation that translates your science into institutional conviction.